[Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins].
An overview of the key concepts about detection of thrombophilic states, establishment of risk factors for thrombosis, the current strategies on diagnosis of thrombophilia, as well as an analysis of the current experience with the use of fractionated and unfractionated heparins, is presented. It is well known that thrombotic disease is multifactorial and that its treatment must be interdisciplinary and multidisciplinary in order to perform an opportune diagnosis and to establish an adequate prophylaxis and anti-thrombotic therapy. Even though several advantages are observed when low molecular weight heparins are used, unfractionated heparins still have some specific indications. Furthermore, under specific conditions, they can work synergistically to achieve a maximal effect on the thromboembolic states. We propose that every medical unit should establish its own criteria and diagnostic and therapeutic algorithms that allow to detect, to diagnose, and to treat the thrombotic events in the best way thus diminishing the morbidity and mortality associated with these thrombotic events.
Lobato-Mendizábal
E
E
Hospital Universitario de Puebla. elobato@prodigy.net.mx
Majluf-Cruz
A
A
D000925:Anticoagulants / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D019851:Thrombophilia / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin
Trombofilia, tromboembolia y el uso de las heparinas no fraccionadas y de bajo peso molecular.